Cash & Leverage
P/E ratio divided by the earnings growth rate. Peter Lynch's tool for checking whether a higher P/E is actually justified by faster growth. PEG ≤ 1.0 is Lynch's "fairly priced" threshold.
Formula
P/E Ratio / Annual EPS Growth Rate (%)PEG History
Historically priceyAbove avgAround avgBelow avgHistorically cheap
No data available
How to read this chart
A low PEG vs the stock's own history suggests the market may not be fully pricing in the growth rate — the combination of P/E and growth looks unusually attractive.
Key caveats
- Only meaningful for businesses with real, consistent earnings growth. Irrelevant for cyclicals, early-stage companies, and income stocks.
- Forward PEG is based on analyst estimates that are frequently optimistic — treat it as a sanity check, not a primary signal.
Is NBIX PEG High or Low Right Now?
Neurocrine Biosciences, Inc.'s PEG is currently 2.5, which is above average relative to its 10-year historical range. The 10-year median PEG for NBIX is approximately 0.9. See all NBIX valuation metrics →
Pro — up to 30-year history
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.